BIBAN
2.3.2023 15:06:42 CET | Business Wire | Press release
Biban, Saudi Arabia’s largest start-up, SME, and entrepreneurship conference, takes place between March 9 and March 13, 2023, at the Riyadh Front Exhibition & Conference Center.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005517/en/
Biban 2023 will feature a diverse range of speakers, high-level talks and sessions throughout its five days (Graphic: AETOSWire)
Biban held its first edition in 2017, and is organized by Monsha’at, the Small and Medium Enterprises General Authority of the Kingdom of Saudi Arabia.
This year, international audiences will benefit from more highlights than ever before, with the forum strongly positioned to foster tangible opportunities.
Biban 2023 will host the Global Finals of the Entrepreneurship World Cup (EWC), one of the biggest and most diverse start-up pitch competitions and support programs of its kind. Since its inception, over 400,000 entrepreneurs from 200 countries have registered. This year, the finalists will compete for up to $1 million in cash prizes.
At Biban 2023, international guests can network and collaborate with government authorities, entrepreneurs, and investors - from the Kingdom and beyond. Additionally, the forum provides access to growing markets, including E-Commerce, FinTech, F&B, and others.
Attendees can also learn about the support - financial and other kinds - that are available to foreigners starting a business in Saudi Arabia.
Making up the engaging themed areas at the forum are nine “Doors”, which include:
- Start-up Door: Featuring incubators, business accelerators and start-ups
- Enablement Door: Hosting agencies that enable entrepreneurial business owners
- Funding Door: Providing start-ups and SMEs with information on where to secure funding and how to overcome financial challenges
- Growth Door: Educating SME owners on areas that help grow their businesses - marketing, strategy, innovation, and much more
Biban 2023 also welcomes a roster of over 350 speakers from the Kingdom and across the world, which include:
- HE Lee Young: Minister of SMEs and Start-ups, Republic of Korea
- Steve Chen: CTO and Co-Founder of YouTube
- Jeff Hoffman: Chairman of the Board, Global Entrepreneurship Network (GEN)
- Chris Barton: Founder and Creator of Shazam
Saudi Arabia is emerging as a key player in the global start-up scene. The Global Entrepreneurship Monitor’s (GEM) 2022 National Entrepreneurship Context Index reported that the Kingdom is now the second-best economy in the world to start a business, reflecting a rapidly advancing start-up ecosystem, and a wealth of business opportunities for local and international entrepreneurs.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005517/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
